Skip to main content

Global HIV Diagnostics Market Growth Anticipated Across High-Burden Nations With 10% CAGR 2030

 

The global HIV diagnostics market is expected to grow at a CAGR of ~10% during the forecast period. Rising prevalence of HIV globally, supportive government initiatives, increasing awareness about early detection, and growing adoption of rapid self-test kits and point-of-care diagnostics are key factors driving the market growth. However, higher costs of advanced HIV diagnostic technologies, lack of proper infrastructure in low and middle-income regions, and social stigma remain significant barriers to the widespread adoption of HIV testing. 

HIV diagnostics refer to the methods and procedures used to detect the presence of Human Immunodeficiency Virus (HIV). Accurate and timely diagnosis not only helps in appropriate medical treatment but also helps prevent further transmission within communities. Some of the HIV diagnostic tests include:

  • Antibody Tests: These are the most common initial screening tools, which detect antibodies produced by the immune system in response to HIV infection
  • Antigen/Antibody Combination Tests: Also known as 4th generation tests, these detect both HIV antibodies and the p24 antigen, which appears soon after infection. This combined detection enables earlier identification of HIV infections compared to tests that detect only antibodies
  • Nucleic Acid Tests (NATs): These tests identify the actual genetic material (RNA) of the virus in the blood. NATs are highly sensitive and are used for early detection and to monitor viral load in infected individuals
  • Rapid Diagnostic Tests (RDTs): These are point-of-care tests that deliver results within 20 to 30 minutes using blood or oral fluids. These tests are widely used in community settings and outreach programs due to their convenience and speed
  • Self-Testing Kits: Designed for personal use; these kits allow individuals to collect samples and test themselves for HIV at home. They increase accessibility and reduce the stigma associated with clinical testing

These diagnostic methods play a crucial role in HIV prevention, treatment, and management by enabling healthcare professionals to promptly diagnose HIV infection, initiate appropriate interventions, and prevent further transmission of the virus.

Download a free sample report for in-depth market insights
https://meditechinsights.com/hiv-diagnostics-market/request-sample/

Government initiatives and global funding: expanding access to HIV diagnostics

Government initiatives and global funding programs aimed at diagnosing and reducing the rising incidences of HIV/AIDS are playing a key role in driving the HIV diagnostics market. Across the globe, public health organizations are partnering with governments to make HIV testing more accessible and affordable. These efforts are backed by government-funded programs which are strategically planned to improve public health outcomes. For instance, the US led PEPFAR (President’s Emergency Plan for AIDS Relief) is a landmark global initiative to increase HIV testing and has helped millions of people around the world to get tested for HIV. Similarly, the Global Fund provides financial and logistical support to increase the HIV testing programs, especially in regions like sub-Saharan Africa and Southeast Asia, where the rate of HIV infections is high. National governments are also stepping up. According to an article by UNAIDS, countries such as South Africa and Brazil have also made HIV testing a central part of public healthcare and increased access in rural and remote areas through mobile clinics and point-of-care diagnostic tools.

In addition to large-scale testing campaigns, governments are supporting innovation in HIV diagnostic techniques by speeding up regulatory approvals, funding for research and development. Overall, strong government support and public awareness programs are significantly improving access to HIV testing and helping reach more people around the world. For Instance,

  • In December 2024, the Global Fund and PEPFAR announced a coordinated effort to provide lenacapavir, a long-acting injectable HIV pre-exposure prophylaxis (PrEP), to at least 2 million people over three years. This collaboration is supported by the Children’s Investment Fund Foundation and the Bill & Melinda Gates Foundation, aiming to reduce HIV infection rate
  • In January 2024, the Global Fund approved US$9.2 billion in new grants to support HIV and other disease awareness and testing programs across more than 70 countries. This funding aims to strengthen health systems and expand access to essential diagnostics and treatments, significantly impacting the HIV diagnostics market

From clinics to comfort: the growing adoption of HIV self-test kits

In recent years, the shift towards self-testing of HIV at home has gained remarkable momentum. This change is mainly driven by technological advancements and a growing focus on privacy, convenience and accessibility for HIV testing. Lately, multiple innovations have taken place for developing more accurate and user-friendly HIV self-test kits. Companies have developed HIV test kits which use an oral swab to detect HIV antibodies and give results in approximately 20 minutes. These tests have demonstrated high levels of sensitivity and specificity, which makes them more reliable and has reduced the discomfort often associated with blood-based diagnostic methods.

Governments and health organizations around the world are increasingly including HIV self-testing in their public health strategies to improve early detection and reduce transmission of the virus. Self-testing kits allow individuals to test in the privacy of their homes, which also reduces the stigma often associated with HIV testing and is especially beneficial for people who feel anxious or uncomfortable about visiting healthcare centers for HIV diagnosis. The increasing adoption of HIV self-testing is expanding access to HIV testing, reducing social stigma, and supporting early detection and treatment efforts. For instance,

  • In January 2025, OraSure Technologies received FDA approval for its OraQuick HIV Self-Test, to be used by individuals aged 14 and older, increasing access among adolescents in the US
  • In June 2023, Newfoundland Diagnostics partnered with Atomo Diagnostics to sell HIV rapid self-test kits in retail outlets like Tesco across the UK/EU, marking the first commercial HIV self-test supply in mainstream European retail channels
  • In April 2023, Abbott partnered with Population Services International (PSI) to offer HIV self-test kits at a fixed, affordable price in low- & middle‑income countries, thereby expanding access and reducing social stigma associated with clinic visits

Competitive Landscape Analysis

The global HIV diagnostics market is marked by the presence of established and emerging market players such as Abbott Laboratories, F. Hoffmann-La Roche Ltd., BioMérieux S.A., Siemens Healthineers, Danaher Corporation, OraSure Technologies, Chembio Diagnostics Inc., Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., and Hologic, Inc., among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Unlock key data with a sample report for competitive analysis:
https://meditechinsights.com/hiv-diagnostics-market/request-sample/

Global HIV Diagnostics Market Segmentation

This report by Medi-Tech Insights provides the size of the global HIV diagnostics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, test type, and end user.

Market Size & Forecast (2023-2030), By Product, USD Million

  •  
    • Reagents & Consumables
    • Instruments/Devices
    • Software & Services

Market Size & Forecast (2023-2030), By Test Type, USD Million

  •  
    • Antibody Tests
    • Antigen/Antibody Combination Tests
    • Nucleic Acid Tests (NAT)
    • Viral Load Testing
    • Other

Market Size & Forecast (2023-2030), By End-user, USD Million

  •  
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Home Care Setting
    • Research Institutes
    • Blood Banks

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

 About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more